ライフサイエンスコーパス: referable

1 ifying advanced AMD (82% vs. 81-92% or 89%), referable AMD (87% vs. 90-92% or 96%), or on the 4-step

2 nefits and harms of primary care-feasible or referable behavioral counseling interventions to prevent

3 ligence performance for overall detection of referable cases (both DR and other conditions) was as fo

4 ning, 8.3% of the 180 study participants had referable diabetic eye disease, 13.3% had vision-threate

5 as moderate and worse diabetic retinopathy, referable diabetic macular edema, or both, were generate

6 telligence system, but both nonreferable and referable diabetic retinopathy (including diabetic macul

7 ibits high diagnostic accuracy for detecting referable diabetic retinopathy (pooled sensitivity 95%,

8 e diagnostic accuracy of EyeArt in detecting referable diabetic retinopathy (rDR) from color fundus p

9 Referable diabetic retinopathy (RDR) was defined for all

10 d specificity of the algorithm for detecting referable diabetic retinopathy (RDR), defined as moderat

11 The performance metrics for referable diabetic retinopathy and macular edema were ab

12 insulin requirement, chronic kidney disease, referable diabetic retinopathy and major adverse cardiov

13 An AI model was trained to classify referable diabetic retinopathy as an exemplar use case.

14 suggests when abnormal (diseased) data, ie, referable diabetic retinopathy in this study, were not a

15 seful in identifying images with and without referable diabetic retinopathy.

16 gh sensitivity and specificity for detecting referable diabetic retinopathy.

17 y efficacy end point was the first record of referable disease after randomization, a composite of re

18 ears, 539 participants (14.6%) experienced a referable disease event in the aspirin group, compared w

19 of 6.5 years, 548 participants (14.8%) had a referable disease event in the omega-3 FAs group, compar

20 Secondary and tertiary outcomes included the referable disease outcome stratified by the severity of

21 The positive predictive value for detecting referable disease was 71.3%.

22 to the first postrandomization recording of referable disease, a composite of referable retinopathy

23 rgest overall AUC on OCTA for distinguishing referable DR (0.905).

24 raining, optimization, and testing to detect referable DR ([refDR], defined as moderate nonproliferat

25 Identification of eyes with either DR or referable DR (moderate nonproliferative DR or DME or wor

26 each eye were used to predict progression to referable DR (RDR) in the second image.

27 and specificity were calculated for any DR, referable DR (refDR), and vision-threatening DR (vtDR).

28 d 2 to 3 OCTA parameters were able to detect referable DR and PDR.

29 l but significant increment in prediction of referable DR beyond grade (increase in C-statistic of 0.

30 ptable performance for the identification of referable DR despite challenging image capture condition

31 ed a deep learning system (DLS) that detects referable DR from retinal images acquired using handheld

32 e FAZ performed better than GPD in detecting referable DR in the SCP (P = 0.025) but not the DCP or f

33 The optimal model for detecting referable DR included only 2 parameters: DCP GPD and FAZ

34 ers), highest-performing model for detecting referable DR or proliferative DR (PDR) based on the quas

35 The sensitivity of the defined referable DR was 88.7% (95% CI 81.7-93.8%) for grader 1

36 Individual probability of developing referable DR was estimated using a generalised linear mo

37 Referable DR was present in 17.3%, 39.1%, and 48.0% of t

38 , 47% of those without and 44% of those with referable DR were female, mean diabetes duration was 21

39 , 44% of those without and 42% of those with referable DR were female, mean diabetes duration was 9 a

40 tic retinopathy (DR) at risk of vision loss (referable DR) needs to be identified by retinal screenin

41 uracy in the detection and classification of referable DR, but a lesser degree of accuracy in the det

42 ications for interval disease risks (IDs) of referable DR, disparities in ID between groups or indivi

43 For identifying referable DR, the average PCP's accuracy was 81.0% unass

44 For detecting PDR within referable DR, the best model included DCP VD, SCP GPD, a

45 cal role in identifying eyes with clinically referable DR.

46 owed no significant difference in discerning referable DR.

47 meters and both were comparable in detecting referable DR.

48 ferative DR, and 15 with DME) had clinically referable DR.

49 had the largest AUC for detecting clinically referable eyes (AUC = 0.965, SN = 97.2%, SP = 84.8%), wh

50 Referable eyes for DR were 11.84%, with an additional 13

51 Clinically referable eyes were defined as moderate nonproliferative

52 cits may better distinguish these clinically referable eyes with DR than standard vessel density para

53 ghly sensitive test for detecting clinically referable eyes without adjusting for covariates (AUC = 0

54 vidence base on interventions feasible in or referable from primary care settings to prevent child ma

55 Among 12 050 identified patients with referable glaucoma (52.3% female), 6827 (56.7%) complete

56 ity of 0.93 (95% CI: 0.89-0.96) in detecting referable glaucoma (definite perimetric glaucoma) when c

57 ing sensitivity and specificity in detecting referable glaucoma from remote vision centers in souther

58 ent with glaucoma specialist's diagnosis for referable glaucoma participants.

59 ios AI identified 39 participants (13%) with referable glaucoma.

60 , assessed for glaucomatous ONH features and referable GON (defined as ONH appearance worrisome enoug

61 urve (AUC), sensitivity, and specificity for referable GON and glaucomatous ONH features.

62 The algorithm's AUC for referable GON was 0.945 (95% confidence interval [CI], 0

63 orithm, the most crucial features related to referable GON were: presence of vertical cup-to-disc rat

64 hm trained on fundus images alone can detect referable GON with higher sensitivity than and comparabl

65 taset A (1205 images, 1 image/patient; 18.1% referable), images adjudicated by panels of GSs; dataset

66 ataset B (9642 images, 1 image/patient; 9.2% referable), images from a diabetic teleretinal screening

67 ataset C (346 images, 1 image/patient; 81.7% referable), images from a glaucoma clinic.

68 guish the disease-free/early stages from the referable intermediate/advanced stages.

69 omparison to detection of any level of DR, a referable level DR (moderate non-proliferative DR and le

70 mages, provides a valid modality to identify referable level of DR.

71 ening not only for its accuracy in detecting referable-level disease, but also for improving screenin

72 f referable retinopathy (R(2) or R(3a/s)) or referable maculopathy (M(1)) based on the grading criter

73 ion, a composite of referable retinopathy or referable maculopathy based on the grading criteria defi

74 ening DR (STDR; defined as proliferative DR, referable maculopathy, or both) was 21.0% (95% CI, 16.7%

75 ms of screening and primary care-feasible or referable nonsurgical weight-loss interventions.

76 her AI matched any clinical diagnosis, be it referable or not, sensitivity was 85.67% (95% CI, 84.12-

77 for any retinopathy, 93.8% (92.9%-94.6%) for referable retinopathy (human graded as either ungradable

78 cording of referable disease, a composite of referable retinopathy (R(2) or R(3a/s)) or referable mac

79 disease after randomization, a composite of referable retinopathy or referable maculopathy based on

80 systems achieved acceptable sensitivity for referable retinopathy when compared with that of human g

81 for any retinopathy, 85.0% (83.6%-86.2%) for referable retinopathy, 97.9% (94.9%-99.1%) for prolifera

82 inical trial, primary care, and primary care-referable settings.

83 between groups or individuals, time spent in referable state before screening (sojourn time), and wor

84 ic thyroid, surveillance, or without thyroid-referable symptoms (asymptomatic).

85 ncers discovered in patients without thyroid-referable symptoms compared with symptomatic detection.

86 eralded by an increased incidence of thyroid-referable symptoms in patients presenting with disease.

87 thyroid findings discovered without thyroid-referable symptoms, 14% (184) for endocrine conditions,

88 omatic and 51% (310 patients) had no thyroid-referable symptoms.

89 re discovered in patients who had no thyroid-referable symptoms; on average, these cancers were small

90 pecimens are not rubidgeine, and instead are referable to Inostrancevia, a taxon previously thought t

91 ion did cause serious functional impairment, referable to interruption of binding of delta to F(1).

92 ch also incorporates all material previously referable to Kenyapithecus africanus.

93 pression and other neurobiological processes referable to known actions of this neuropeptide.

94 d by aberrant regional cortical excitability referable to mGluR5-mTOR signaling.

95 quenching at approximately 1.5% pyrenyl-PE) referable to nonspecific interaction of pyrenyl-PE with

96 the first description of a kidney phenotype referable to one or more Wnt receptors and demonstrates

97 tions for antagonists or agonists, plausibly referable to receptor inhibition or activation.

98 hown that the non-neuroinvasive phenotype is referable to single amino acid changes in glycoprotein D

99 ral [38%]); clinical seizure characteristics referable to specific lobe (occipital [14%], temporal [3

100 2B2 G. tabacina polyploids contain plastomes referable to the A and B diploid plastome groups of subg

101 meters in length, is an advanced allosauroid referable to the African genus Carcharodontosaurus.

102 erformed to treat patients with chronic pain referable to the brachial plexus.

103 troke, or other neurologic signs or symptoms referable to the carotid arteries.

104 schemic attack, or other neurologic symptoms referable to the carotid arteries.

105 ocognitive disorder, particularly with tests referable to the episodic memory and motor domains.

106 so report on a peculiar tanaidacean specimen referable to the fossil family Alavatanaidae, Daenerytan

107 Dyspepsia is a complex of symptoms referable to the gastroduodenal region of the gastrointe

108 formation, medical history, and any symptoms referable to the identified CCM lesion.

109 Data referable to the time period of IV allopurinol administr

110 Specimens referable to the two recognized morphospecies of Tricera

111 are used to evaluate patients with symptoms referable to the upper digestive tract.

112 e of the five donors had documented symptoms referable to their urinary tract.